重组人骨保护素对激素性股骨头坏死患者骨密度及髋关节Harris评分的影响

被引：21

作者：

杨登峰 ^{[1
]}

阮文辉 ^{[1
]}

谢鹏 ^{[1
]}

程延 ^{[2
]}

石宇 ^{[3
]}

机构：

[1] 陕西省汉中市中心医院骨科

[2] 陕西中医学院附属医院骨科

[3] 兵器工业卫生研究所医院骨科

来源：

现代生物医学进展 | 2016年 / 16卷 / 16期

关键词：

重组人骨保护素; 激素性股骨头坏死; 骨密度; 髋关节功能;

D O I：

10.13241/j.cnki.pmb.2016.16.028

中图分类号：

R681.8 [下肢骨];

学科分类号：

100220 [骨科学];

摘要：

目的:探讨重组人骨保护素对于激素性股骨头坏死患者的骨密度和髋关节Harris评分的影响。方法:选取我院骨科已经确诊的110例激素性股骨头坏死患者,随机分为对照组(给予仙灵骨葆胶囊)和观察组(给予仙灵骨葆胶囊和重组人骨保护素),连续治疗4周,检测并比较两组患者治疗前后的骨密度、髋关节Harris评分、血清抗酒石酸酸性磷酸酶(TRAP)、Ⅱ型胶原羧基端端肽(CTX-Ⅱ)水平以及复发率变化。结果:与对照组相比较,观察组患者腰椎骨和股骨近端的骨密度较高平(P<0.05);髋关节Harris评分总有效率(92.73%)显著高于对照组(76.36%)(P<0.05)。两组血清TRAP及CTX-Ⅱ水平显著低于治疗前,且试验组血清TRAP及CTX-Ⅱ水平显著低于对照组(P<0.05),与对照组相比,观察组复发率较低(P<0.05)。结论:重组人骨保护素能够抑制骨吸收,提高骨密度和强度,改善髋关节功能,有望成为激素性股骨头坏死的新型治疗方法。

引用

页码：3108 / 3111

页数：4

共 8 条

[1]

Prevention of Osteopenia and Dyslipidemia in Rats after Ovariectomy with Combined Aspirin and Low-dose Diethylstilbestrol.[J].LIN Si En;HUANG Jian Ping;WU Ling Zhi;WU Tie;CUI Liao;.Biomedical and Environmental Sciences.2013, 04

[2]

Treating osteoporosis by targeting parathyroid hormone to bone [J].

Ponnapakkam, T. ;

Katikaneni, R. ;

Sakon, J. ;

Stratford, R. ;

Gensure, R. C. .

DRUG DISCOVERY TODAY, 2014, 19 (03) :204-208

[3]

Protection from cyclophosphamide-induced ovarian damage with bone marrow-derived mesenchymal stem cells during puberty.[J].Sevtap Kilic;Ferda Pinarli;Candan Ozogul;Nicel Tasdemir;Gulce Naz Sarac;Tuncay Delibasi.Gynecological Endocrinology.2013, 2

[4]

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance [J].

Yu, Xiuchun ;

Kong, Weiqing ;

Zheng, Kai .

ONCOLOGY LETTERS, 2013, 5 (04) :1133-1139

[5]

Fruits and dietary phytochemicals in bone protection [J].

Shen, Chwan-Li ;

von Bergen, Vera ;

Chyu, Ming-Chien ;

Jenkins, Marjorie R. ;

Mo, Huanbiao ;

Chen, Chung-Hwan ;

Kwun, In-Sook .

NUTRITION RESEARCH, 2012, 32 (12) :897-910

[6]

Soy protein with or without isoflavones failed to preserve bone density in gonadal hormone–deficient male rat model of osteoporosis.[J].Shanil S. Juma;Zahra Ezzat-Zadeh;Dania A. Khalil;Shirin Hooshmand;Mohammed Akhter;Bahram H. Arjmandi.Nutrition Research.2012, 9

[7]

Systemic intermittent parathyroid hormone treatment improves osseointegration of press-fit inserted implants in cancellous bone.[J].Henrik Daugaard;Brian Elmengaard;Troels Torp Andreassen;Anders Lamberg;Joan Elisabeth Bechtold;Kjeld Soballe.Acta Orthopaedica.2012, 4

[8]

Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization [J].

Karim, Roksana ;

Dell, Richard M. ;

Greene, Denise F. ;

Mack, Wendy J. ;

Gallagher, J. Christopher ;

Hodis, Howard N. .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2011, 18 (11) :1172-1177

← 1 →